Gómez-Guijarro María Dolores, Cavero-Redondo Iván, Saz-Lara Alicia, Pascual-Morena Carlos, Álvarez-Bueno Celia, Martínez-García Irene
Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.
Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca, Chile.
Cogn Neurodyn. 2024 Oct;18(5):3059-3073. doi: 10.1007/s11571-024-10138-5. Epub 2024 Jun 13.
Background: Cognitive impairment, characterized by deficits in cognitive functions and loss of delayed and immediate recall, disproportionately affects individuals aged 65 years and older, particularly those with comorbid cardiovascular conditions such as hypertension and diabetes mellitus. Objective: This study aimed to investigate the potential association between intranasal insulin and cognitive and/or memory impairment, with a specific focus on delayed and immediate recall, considering the rising prevalence of cognitive disorders in the aging population. Methodology: Employing a rigorous systematic approach, we conducted a thorough search of MEDLINE, Scopus, the Cochrane database, and Web of Science from inception to November 23, 2022, identifying relevant randomized clinical trials. Our analyses encompassed three key aspects: (i) assessing the impact of intranasal insulin on cognitive impairment, (ii) evaluating its effect on delayed recall, and (iii) examining its influence on immediate recall. Results: Five studies meeting the inclusion criteria were included. The results underscored a statistically significant effect of intranasal insulin on delayed memory (effect size: 1.37; 95% CI: 0.65 to 2.09) and overall cognition (effect size: 0.58; 95% CI: 0.08 to 1.08). However, no statistically significant effect was observed for immediate memory (effect size: 0.48; 95% CI: -0.00 to 0.96). Conclusions: This study provides compelling evidence supporting the significance and efficacy of intranasal insulin in enhancing delayed recall and overall cognition. The observed effects hold promise for potential therapeutic interventions in addressing cognitive deficits associated with aging and comorbid conditions. The findings emphasize the need for further research to elucidate the underlying mechanisms and optimize the application of intranasal insulin in cognitive enhancement strategies.
The online version contains supplementary material available at 10.1007/s11571-024-10138-5.
背景:认知障碍以认知功能缺陷以及延迟和即时回忆丧失为特征,对65岁及以上的个体影响尤为严重,特别是那些患有高血压和糖尿病等心血管合并症的个体。目的:鉴于老年人群中认知障碍的患病率不断上升,本研究旨在调查鼻内胰岛素与认知和/或记忆障碍之间的潜在关联,特别关注延迟和即时回忆。方法:我们采用严格的系统方法,对MEDLINE、Scopus、Cochrane数据库和Web of Science从创建到2022年11月23日进行了全面检索,以识别相关的随机临床试验。我们的分析包括三个关键方面:(i)评估鼻内胰岛素对认知障碍的影响,(ii)评估其对延迟回忆的影响,以及(iii)检查其对即时回忆的影响。结果:纳入了五项符合纳入标准的研究。结果强调鼻内胰岛素对延迟记忆(效应大小:1.37;95%置信区间:0.65至2.09)和整体认知(效应大小:0.58;95%置信区间:0.08至1.08)有统计学显著影响。然而,即时记忆方面未观察到统计学显著影响(效应大小:0.48;95%置信区间:-0.00至0.96)。结论:本研究提供了有力证据,支持鼻内胰岛素在增强延迟回忆和整体认知方面的重要性和有效性。观察到的效果为解决与衰老和合并症相关的认知缺陷的潜在治疗干预带来了希望。研究结果强调需要进一步研究以阐明潜在机制,并优化鼻内胰岛素在认知增强策略中的应用。
在线版本包含可在10.1007/s11571-024-10138-5获取的补充材料。